Can bad news be good news? For AbbVie (NYSE:ABBV), it can.
The company's top-selling drug, Humira, will begin to face biosimilar competition in Europe later this year. In early 2023, biosimilars to Humira will hit the U.S. market. There's no doubt that sales for the drug will decline over the next few years. That's the bad news.